Treprostinil (Orenitram) vs Treprostinil (Yutrepia, Liquidia)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Treprostinil (Orenitram)

Marketed by United Therapeutics

Approved in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT00325403 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.

Reported efficacy

Six Minute Walk Distance (6MWD) (Baseline and Week 12): Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) (met)

Result source: NCT00325403

Treprostinil (Yutrepia, Liquidia)

Marketed by Liquidia Corporation

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin analogue, inhaled dry powder)
Weak signal

NCT03399604 · Phase 3 · completed

The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.

Next expected readout: May 2027 · NCT07759804 (registry estimate)

Reported efficacy

Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)

Result source: NCT03399604

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Treprostinil (Orenitram): 4 of 4 rows · Treprostinil (Yutrepia, Liquidia): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTreprostinil (Orenitram)Treprostinil (Yutrepia, Liquidia)
Dropout rate
21.9%a
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
42.1%
NCT01560637 · Phase 3 · registry result, not featured evidence
76.7%
NCT01027949 · Phase 3 · registry result, not featured evidence
57.2%
NCT01560624 · Phase 3 · registry result, not featured evidence
12.1%
NCT00325442 · Phase 3 · registry result, not featured evidence
10%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
24%LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Discontinued due to AEs
—a
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
13.4%
NCT01560637 · Phase 3 · registry result, not featured evidence
19.2%
NCT01027949 · Phase 3 · registry result, not featured evidence
—
NCT01560624 · Phase 3 · registry result, not featured evidence
—
NCT00325442 · Phase 3 · registry result, not featured evidence
10%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
—LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Serious AEs
17.9%a
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
43.8%
NCT01560637 · Phase 3 · registry result, not featured evidence
61.2%
NCT01027949 · Phase 3 · registry result, not featured evidence
33.5%
NCT01560624 · Phase 3 · registry result, not featured evidence
18.4%
NCT00325442 · Phase 3 · registry result, not featured evidence
50%Cohort 1 (Transitioning From Paren
NCT02276872 · Phase 2 · registry result, not featured evidence
0%Cohort 2 (Transitioning From Inhal
NCT02276872 · Phase 2 · registry result, not featured evidence
33.3%Cohort 3 (Add-on to Current PAH Th
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
12.4%LIQ861 Add-On
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3
show 1 more result
—LIQ861 Inhaled Treprostinil
NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3
Most frequent reported AEs
a
headache 62.9% (placebo 19.5%)
diarrhea 30.5% (placebo 15.6%)
nausea 29.8% (placebo 18.2%)
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 7 more results
headache 69.8%
diarrhoea 66.2%
flushing 42.8%
NCT01560637 · Phase 3 · registry result, not featured evidence
headache 78.1%
diarrhoea 66.2%
nausea 56.5%
NCT01027949 · Phase 3 · registry result, not featured evidence
headache 74.9% (placebo 34.9%)
diarrhoea 69.4% (placebo 28.5%)
flushing 44.5% (placebo 7.8%)
NCT01560624 · Phase 3 · registry result, not featured evidence
headache 86.2% (placebo 36.9%)
nausea 64.4% (placebo 34.1%)
diarrhea 60.9% (placebo 27.3%)
NCT00325442 · Phase 3 · registry result, not featured evidence
vomiting 90%
nausea 70%
diarrhoea 60%
NCT02276872 · Phase 2 · registry result, not featured evidence
headache 80%
diarrhoea 70%
cough 50%
NCT02276872 · Phase 2 · registry result, not featured evidence
headache 100%
diarrhoea 75%
nausea 75%
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
cough 33.9%
headache 19%
upper respiratory tract infection 14.9%
NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Treprostinil (Orenitram)

6MWD - Change 25 vs -5 placebo m @ 12wk
absolute change · m
Change in 6MWD from Baseline to Week 12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
16.5 vs 5.8 placebo m @ 12wk
Change in 6MWD from Baseline to Week 12
NCT00325442 · Phase 3 · registry result, not featured evidence
6MWD - Change 8 vs 0 placebo m @ 11wk
absolute change · m
Change in 6MWD from Baseline to Week 11
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
6MWD - Change 17 vs 0 placebo m @ 8wk
absolute change · m
Change in 6MWD from Baseline to Week 8
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
15 vs 7 placebo m @ 8wk
Change in 6MWD from Baseline to Week 8
NCT00325442 · Phase 3 · registry result, not featured evidence
6MWD - Change 7 vs 0 placebo m @ 4wk
absolute change · m
Change in 6MWD from Baseline to Week 4
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
show 1 more result
5.5 vs 2.1 placebo m @ 4wk
Change in 6MWD from Baseline to Week 4
NCT00325442 · Phase 3 · registry result, not featured evidence
Clinical Worsening 9.9% (n=151) vs 10.4% (n=77) placebo @ 12wk
event count · % of participants
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 · converted to % from 15 participants as posted
show 1 more result
4.6% (n=174) vs 6.8% (n=176) placebo @ 16wk*
NCT00325442 · Phase 3 · registry result, not featured evidence · converted to % from 8 participants as posted
Borg Dyspnea 0 vs 0 placebo score @ 12wk
absolute change · score
Change in Borg dyspnea score from Baseline to Wk12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
Dyspnea-Fatigue Index -0.3 vs -0.3 placebo score @ 12wk
absolute change · score
Change in dyspnea-fatigue index from BL to Wk 12
NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3
Six Minute Walk Change 20.1 m @ 48wk
absolute change · m
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
Borg Dyspnea -0.49 score @ 48wk
absolute change · score
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
show 3 more results
-1.56 score @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence
0.05 score @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence
-0.83 score @ 24wk
NCT02276872 · Phase 2 · registry result, not featured evidence · combination
WHO Functional Class -0.2 score @ 48wk
absolute change · score
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
NT-proBNP -179.23 pg/mL @ 48wk
absolute change · pg/mL
No placebo or comparator arm
NCT01560637 · Phase 3 · registry result, not featured evidence
6MWD - Change 22 m @ 48wk
absolute change · m
Extension (open-label)
No placebo or comparator arm
NCT01027949 · Phase 3 · registry result, not featured evidence

+ 18 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Orenitram)'s landscape · Treprostinil (Yutrepia, Liquidia)'s landscape